LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...
Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products by agreeing to cap costs at $35 per month.
Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.
Meanwhile, in case Novo Nordisk can’t convince regulators of oral semaglutide’s merits first time around, it has a large-scale cardiovascular outcome study called SOUL in preparation that ...